B8R 20-27 (H-2 Kb) TSYKFESV
€105.00*
Description
The linear peptide B8R 20-27, with the amino acid sequence TSYKFESV (epitope ID 66504), is a well-established H2-Kb-restricted epitope conserved among various Vaccinia virus strains. [1] It is part of the:
- Soluble interferon gamma receptor OPG193 (UniProt:P24770) from Vaccinia virus
- IFN-gamma receptor (UniProt:Q66793) from Ectromelia mousepox virus
- IFN-gamma receptor-like protein (UniProt:G0XTP5) from Cowpox virus
The Vaccinia virus was the live vaccine used to eradicate smallpox. It belongs to the orthopoxvirus family and provides protection against a range of orthopoxviruses. Currently, the most concerning of these is the monkeypox virus, but human cowpox infections are also being reported regularly in Europe. [1]
The B8R 20-27 peptide, TSYKFESV, is also contained in recombinant and non-recombinant Modified Vaccinia virus Ankara (MVA). [1] The Modified Vaccinia virus Ankara has greatly reduced virulence and can no longer replicate in most mammalian cells. [2] It is often used as a vaccine vector, due to its cost-effectiveness, safety, and high immunogenicity. Recombinant MVA vaccines can generate robust humoral and cellular immune responses against various pathogens.
In vaccine development, the B8R 20-27 peptide is used as a positive control to demonstrate that a lack of response is not due to immunization failure. The vaccinia virus B8R gene encodes a homolog of the secreted IFN-γ receptor. By binding to IFN-γ, B8R neutralizes its antiviral activity and is therefore involved in virus evasion of host interferon responses. [1,3]
You can read a current application example in our blog post "Vaccines against Chlamydia trachomatis: Immunogenicity analysis via peptide pool" or view the original publication [4] via the link under the References tab.
TechData
| Sequence: | TSYKFESV |
| Delivery: | 1-3 days |
| C-Terminus: | OH |
| N-Terminus: | H |
| Amount: | 1 mg |
| Counterion: | TFA |
| Protein: | Vaccinia virus WR epitope B8R |
| UniProt Id: | P24770, Q66793, G0XTP5 |
| IEDB Id: | 66504 |
| Species: | Vaccinia virus (VACV) |
| Allele: | H-2 Kb |
| Application: | Flow Cytometry |
| Indication: | Infectious disease, Control |
| Purity: | 95% HPLC-MS |
Documents
References
- Flesch, Inge E A et al. “Extent of Systemic Spread Determines CD8+ T Cell Immunodominance for Laboratory Strains, Smallpox Vaccines, and Zoonotic Isolates of Vaccinia Virus.” Journal of immunology, vol. 195,5 (2015): 2263-72. doi:10.4049/jimmunol.1402508
- Kaynarcalidan, Onur et al. “Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design.” Biomedicines vol. 9,12 1780. 26 Nov. 2021, doi:10.3390/biomedicines9121780
- Jacobs, Bertram L et al. “Vaccinia virus vaccines: past, present and future.” Antiviral research vol. 84,1 (2009): 1-13. doi:10.1016/j.antiviral.2009.06.006
- Andreacchio, Giuseppe et al. “Viral Vector-Based Chlamydia trachomatis Vaccines Encoding CTH522 Induce Distinct Immune Responses in C57BL/6J and HLA Transgenic Mice.” Vaccines vol. 12,8 944. 22 Aug. 2024, doi:10.3390/vaccines12080944
More Control Peptides and Peptide Pools
